Literature DB >> 27812929

MiR-212/132 is epigenetically downregulated by SOX4/EZH2-H3K27me3 feedback loop in ovarian cancer cells.

Lin Lin1, Zhiwen Wang2, Haihong Jin3, Hongzhen Shi1, Zhihong Lu4, Zhenqin Qi5.   

Abstract

Both miR-212 and miR-132 are usually downregulated in ovarian cancer and act as tumor suppressors. However, the mechanism of their downregulation in ovarian cancer is not clear. In this study, we investigated the regulative effects of miR-212 and miR-132 on SOX4 expression in ovarian cancer cells and also studied whether there is a feedback regulation between miR-212/miR-132 and SOX4 via an epigenetic mechanism. The results showed that both EZH2 and SOX4 overexpressions significantly repressed miR-212 and miR-132 expressions in SKOV3 and OV2008 cells. Immunoprecipitation assay showed that there are interactions among SOX4, EZH2, and H3K27me3, and ChIP assay confirmed significant enrichment of EZH2 and H3K27me3 in the promoter region of miR-212/132. Both pri-miR-212 and pri-miR-132 expressions decreased after enforced EZH2 or SOX4 expression. Western blot and dual-luciferase assay confirmed that miR-212 and miR-132 can target the same sites in the 3'UTR of SOX4 mRNA and suppress its expression in ovarian cancer cells. MiR-132 or miR-212 overexpression or knockdown of endogenous SOX4 reduced epithelial-mesenchymal transition (EMT)-like properties. Therefore, we infer that the SOX4/EZH2 complex can silence miR-212 and miR-132 expressions via binding to the promoter region and promoting H3K27me3, while miR-212 and miR-132 can directly bind to the 3'UTR of SOX4 and suppress its expression. This forms a MiR-132/212-SOX4/EZH2-H3K27me3 feedback loop in ovarian cancer cells. Functionally, SOX4 is a downstream effector of miR-212/132 modulating EMT of ovarian cancer cells.

Entities:  

Keywords:  EZH2; H3K27me3; Ovarian cancer; SOX4; miR-132; miR-212

Year:  2016        PMID: 27812929     DOI: 10.1007/s13277-016-5339-9

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  29 in total

Review 1.  The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3.

Authors:  Ru Cao; Yi Zhang
Journal:  Curr Opin Genet Dev       Date:  2004-04       Impact factor: 5.578

2.  DNA methylation silences miR-132 in prostate cancer.

Authors:  A Formosa; A M Lena; E K Markert; S Cortelli; R Miano; A Mauriello; N Croce; J Vandesompele; P Mestdagh; E Finazzi-Agrò; A J Levine; G Melino; S Bernardini; E Candi
Journal:  Oncogene       Date:  2012-02-06       Impact factor: 9.867

3.  The Polycomb group protein EZH2 directly controls DNA methylation.

Authors:  Emmanuelle Viré; Carmen Brenner; Rachel Deplus; Loïc Blanchon; Mario Fraga; Céline Didelot; Lluis Morey; Aleyde Van Eynde; David Bernard; Jean-Marie Vanderwinden; Mathieu Bollen; Manel Esteller; Luciano Di Croce; Yvan de Launoit; François Fuks
Journal:  Nature       Date:  2005-12-14       Impact factor: 49.962

4.  MDC1 promotes ovarian cancer metastasis by inducing epithelial-mesenchymal transition.

Authors:  Xiaolin Liu; Ruifen Dong; Zhijun Jiang; Yuyan Wei; Yingwei Li; Linxuan Wei; Hengzi Sun; Yinuo Li; Ning Yang; Qifeng Yang; Zhaojian Liu; Beihua Kong
Journal:  Tumour Biol       Date:  2015-01-16

5.  Hemimethylation footprints of DNA demethylation in cancer.

Authors:  Chunbo Shao; Michelle Lacey; Louis Dubeau; Melanie Ehrlich
Journal:  Epigenetics       Date:  2009-04-23       Impact factor: 4.528

6.  Epigenetic repression of miR-132 expression by the hepatitis B virus x protein in hepatitis B virus-related hepatocellular carcinoma.

Authors:  Xufu Wei; Cui Tan; Chengyong Tang; Guosheng Ren; Tingxiu Xiang; Zhu Qiu; Rui Liu; Zhongjun Wu
Journal:  Cell Signal       Date:  2013-01-30       Impact factor: 4.315

7.  Methylation in the p53 promoter in epithelial ovarian cancer.

Authors:  Marcela Chmelarova; E Krepinska; J Spacek; J Laco; M Beranek; V Palicka
Journal:  Clin Transl Oncol       Date:  2012-07-19       Impact factor: 3.405

8.  miR-132 targeting E2F5 suppresses cell proliferation, invasion, migration in ovarian cancer cells.

Authors:  Hang Tian; Lei Hou; Yu-Mei Xiong; Jun-Xiang Huang; Wen-Hua Zhang; Yong-Ying Pan; Xing-Rong Song
Journal:  Am J Transl Res       Date:  2016-03-15       Impact factor: 4.060

9.  Current status and implications of microRNAs in ovarian cancer diagnosis and therapy.

Authors:  Mohd Saif Zaman; Diane M Maher; Sheema Khan; Meena Jaggi; Subhash C Chauhan
Journal:  J Ovarian Res       Date:  2012-12-13       Impact factor: 4.234

10.  MicroRNA-101 is repressed by EZH2 and its restoration inhibits tumorigenic features in embryonal rhabdomyosarcoma.

Authors:  Roberta Ciarapica; Rossella Rota; Serena Vella; Silvia Pomella; Pier Paolo Leoncini; Marta Colletti; Beatrice Conti; Victor E Marquez; Antonio Strillacci; Josep Roma; Soledad Gallego; Giuseppe M Milano; Maurizio C Capogrossi; Alice Bertaina
Journal:  Clin Epigenetics       Date:  2015-08-06       Impact factor: 6.551

View more
  5 in total

1.  Prognostic value of MTA1, SOX4 and EZH2 expression in esophageal squamous cell carcinoma.

Authors:  Wenying Liu; Yu Xia; Mengyan Li; Gulinaer Abulajiang; Hui Wang; Liping Su; Chao Li; Yan Shi; Wenjing Zhang; Shanshan Xu; Yuqing Ma
Journal:  Exp Ther Med       Date:  2021-05-03       Impact factor: 2.447

2.  Identification of key microRNAs and genes in preeclampsia by bioinformatics analysis.

Authors:  Shouling Luo; Nannan Cao; Yao Tang; Weirong Gu
Journal:  PLoS One       Date:  2017-06-08       Impact factor: 3.240

Review 3.  The functions and targets of miR-212 as a potential biomarker of cancer diagnosis and therapy.

Authors:  Wenjun Chen; Jing Song; Hongjun Bian; Xia Yang; Xiaoyu Xie; Qiang Zhu; Chengyong Qin; Jianni Qi
Journal:  J Cell Mol Med       Date:  2020-01-13       Impact factor: 5.310

Review 4.  Deregulated miRNA clusters in ovarian cancer: Imperative implications in personalized medicine.

Authors:  Amoolya Kandettu; Divya Adiga; Vasudha Devi; Padmanaban S Suresh; Sanjiban Chakrabarty; Raghu Radhakrishnan; Shama Prasada Kabekkodu
Journal:  Genes Dis       Date:  2022-03-01

5.  microRNA-132 inhibits the proliferation, migration, and invasion of ovarian cancer cells by regulating CT10 oncogenic gene homolog II-related signaling pathways.

Authors:  Haiyan Jiang; Min Dai; Yao Wu; Yansong Dong; Lei Qi; Qinghua Xi; Guiwen Liang
Journal:  Transl Cancer Res       Date:  2020-07       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.